Dr. Katharine “Katie” Grabek is the Chief Scientific Officer and co-founder of Fauna Bio, a biotechnology company dedicated to translating insights from hibernating mammals into human therapeutics. Leveraging her expertise in human medical genetics, she leads research into the unique biological mechanisms of hibernation, aiming to identify novel targets for treating conditions such as metabolic disorders and cardiovascular diseases. Under her leadership, Fauna Bio has developed the Convergence™ AI platform, which integrates comparative genomics to accelerate drug discovery. The company’s innovative approach has led to strategic collaborations, including a partnership with Eli Lilly to explore new obesity treatments. Dr. Grabek’s work exemplifies the potential of cross-species research in advancing human health.